Dbv Technologies is a biopharmaceutical company focused on developing innovative therapies for patients with food allergies, particularly peanut allergies
Utilizing its proprietary Systemic Immunotherapy platform, the company aims to create treatments that help desensitize individuals to allergens, ultimately enhancing their quality of life and reducing the risk of severe allergic reactions. By leveraging advanced medical technology and a rigorous clinical development approach, Dbv Technologies strives to bring novel, breakthrough solutions to the field of immunotherapy for food allergies.
DBV Technologies secured up to $306.9M to advance its Viaskin Peanut program. The funding supports FDA submission, commercialization and ongoing pediatric peanut allergy treatment research.
DBV Technologies secures FDA guidance for Accelerated Approval of its Viaskin Peanut patch, advancing treatment for toddlers with peanut allergies through pivotal trials.
DBV Technologies progresses with regulatory efforts for its Viaskin Peanut patch in the U.S. and Europe, while financial concerns loom as the company seeks additional funding to continue its operations.
